Amesite Inc. filed a Form 8-K on November 13, 2026, disclosing that it received a deficiency notification from Nasdaq on November 11, 2026, for failing to maintain the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Key Highlights

  • Deficiency notice received: Amesite was notified on November 11, 2026, that it is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
  • Triggering period: The closing bid price of the company's common stock from September 30, 2026 to November 10, 2026 fell below the $1.00 minimum for the required 30 consecutive business days.
  • No immediate trading impact: According to the filing, the notification "has no immediate effect on the listing or trading of the Company's common stock," which continues to trade under the symbol "AMST."
  • Initial compliance deadline: The company has 180 calendar days, until May 10, 2027, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
  • Potential second compliance period: If the initial deadline is missed, an additional 180 days may be granted, subject to meeting other Nasdaq continued listing requirements and providing written notice of intent to cure the deficiency.
  • Options under consideration: The company disclosed it may consider "implementing available options, including, but not limited to, implementing a reverse stock split" to regain compliance.

Amesite Discloses Nasdaq Bid Price Deficiency and Compliance Timeline

Amesite Inc. (NASDAQ:AMST), a Delaware-incorporated company headquartered in Detroit, Michigan, reported in its Form 8-K that Nasdaq sent a Notification Letter on November 11, 2026, citing noncompliance with Nasdaq Listing Rule 5550(a)(2). That rule requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), a deficiency is established when the closing bid price remains below $1.00 for 30 consecutive business days, a condition the company's stock met from September 30, 2026 through November 10, 2026, according to the filing.

The filing states that the Notification Letter provides a 180-calendar-day window, expiring May 10, 2027, for Amesite to return to compliance. To satisfy the requirement within that period, the common stock must close at or above $1.00 per share for at least 10 consecutive business days. If Amesite does not meet that threshold by the initial deadline, the filing describes a possible second 180-day extension, contingent on the company meeting The Nasdaq Capital Market's continued listing requirement for market value of publicly-held shares, satisfying all other initial listing standards except the minimum bid price, and notifying Nasdaq in writing of its intention to cure the deficiency, "by effecting a reverse stock split, if necessary."

Should the company fail to qualify for or complete the second compliance period, the filing states that Nasdaq would notify Amesite of a determination to delist its common stock, at which point the company would have the opportunity to appeal to a Hearings Panel. The Form 8-K was signed by Ann Marie Sastry, Ph.D., Chief Executive Officer, on November 13, 2026. The company noted it intends to monitor its closing bid price and may consider available options, including a reverse stock split, as it assesses next steps.

What Was Disclosed

Amesite Inc. disclosed receipt of a Nasdaq deficiency notice for failure to maintain a $1.00 minimum bid price, triggered by closing prices from September 30 to November 10, 2026, with a compliance deadline of May 10, 2027, and no immediate effect on trading.